当地时间6月2日阿斯利康宣布LAURA Ⅲ期试验的积极结果显示Tagrisso（osimertinib）与安慰剂相比对肿瘤有外显子19缺失或外显子21（L858R）突变的不可切除的Ⅲ期表皮生长因子受体突变（EGFRm）非小细胞肺癌（NSCLC）患者进行化放疗（CRT）后的无进展生存期（PFS）有统计学意义和高度临床意义的改善。

智通财经06-03

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2440109354?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-03 07:30","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2440109354","market":"us","top_or_hot":-1,"title":"当地时间6月2日阿斯利康宣布LAURA Ⅲ期试验的积极结果显示Tagrisso（osimertinib）与安慰剂相比对肿瘤有外显子19缺失或外显子21（L858R）突变的不可切除的Ⅲ期表皮生长因子受体突变（EGFRm）非小细胞肺癌（NSCLC）患者进行化放疗（CRT）后的无进展生存期（PFS）有统计学意义和高度临床意义的改善。","media":"智通财经","content":"<div>\n<p>当地时间6月2日阿斯利康宣布LAURA Ⅲ期试验的积极结果显示Tagrisso（osimertinib）与安慰剂相比对肿瘤有外显子19缺失或外显子21（L858R）突变的不可切除的Ⅲ期表皮生长因子受体突变（EGFRm）非小细胞肺癌（NSCLC）患者进行化放疗（CRT）后的无进展生存期（PFS）有统计学意义和高度临床意义的改善。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-03 07:30 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>当地时间6月2日阿斯利康宣布LAURA Ⅲ期试验的积极结果显示Tagrisso（osimertinib）与安慰剂相比对肿瘤有外显子19缺失或外显子21（L858R）突变的不可切除的Ⅲ期表皮生长因子受体突变（EGFRm）非小细胞肺癌（NSCLC）患者进行化放疗（CRT）后的无进展生存期（PFS）有统计学意义和高度临床意义的改善。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2440109354","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2440109354","pubTimestamp":1717371048,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"当地时间6月2日阿斯利康宣布LAURA Ⅲ期试验的积极结果显示Tagrisso（osimertinib）与安慰剂相比对肿瘤有外显子19缺失或外显子21（L858R）突变的不可切除的Ⅲ期表皮生长因子受体","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK4568":"美国抗疫概念","AZN":"阿斯利康","BK4213":"石油与天然气的勘探与生产","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4211":"区域性银行","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","CRT":"CRT信托","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4195":"互助储蓄与抵押信贷金融服务","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","PFS":"Provident Financial Services Inc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4585":"ETF&股票定投概念","BK4007":"制药"},"translate_title":"On June 2, local time, AstraZeneca announced that the positive results of the LAURA phase III trial showed that Tagrisso (osimertinib) had unresectable stage III epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC) patients with chemoradiotherapy (CRT) had a statistically significant and highly clinically significant improvement in progression-free survival (PFS) after chemoradiotherapy (CRT).","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"CRT":1,"PFS":1},"content_text":"当地时间6月2日阿斯利康宣布LAURA Ⅲ期试验的积极结果显示Tagrisso（osimertinib）与安慰剂相比对肿瘤有外显子19缺失或外显子21（L858R）突变的不可切除的Ⅲ期表皮生长因子受体突变（EGFRm）非小细胞肺癌（NSCLC）患者进行化放疗（CRT）后的无进展生存期（PFS）有统计学意义和高度临床意义的改善。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2440109354"}